Edition:
India

Novo Nordisk A/S (NOVOb.CO)

NOVOb.CO on Copenhagen Stock Exchange

349.50DKK
19 Jan 2018
Change (% chg)

kr.7.50 (+2.19%)
Prev Close
kr.342.00
Open
kr.347.80
Day's High
kr.352.25
Day's Low
kr.346.10
Volume
3,603,486
Avg. Vol
2,884,378
52-wk High
kr.352.25
52-wk Low
kr.225.60

Chart for

About

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity... (more)

Overall

Beta: 1.51
Market Cap(Mil.): kr.610,749.88
Shares Outstanding(Mil.): 1,962.56
Dividend: 3.00
Yield (%): 2.44

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.58
EPS (TTM): -- -- --
ROI: -- 14.84 10.60
ROE: -- 16.32 14.19

UPDATE 1-Largest Ablynx investor would consider improved Novo Nordisk bid

BRUSSELS, Jan 18 The largest shareholder in Belgian biotech group Ablynx regards the 2.6 billion euro ($3.2 billion) offer made by Denmark's Novo Nordisk as too low but would be willing to consider a higher figure.

18 Jan 2018

Largest Ablynx shareholder says Novo Nordisk offer is too low

BRUSSELS, Jan 18 The largest shareholder in Belgian biotech group Ablynx said on Thursday that it believed a 2.6 billion euro ($3.2 billion) offer made by Denmark's Novo Nordisk was too low.

18 Jan 2018

LIVE MARKETS-Closing snapshot: European stocks end in positive territory, FTSE at a record

* European shares end higher * Euro rises on German coalition hopes * FTSE on new records as GKN surges * Kering to spin off Puma * Europe stock funds post inflows Jan 12 Welcome to the home for real time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Danilo Masoni. Reach him on Messenger to share your thoughts on market moves: danilo.masoni.thomsonreuters.com@reuters.net CLOSING SNAPSHOT: EUROPEAN

12 Jan 2018

Ablynx soars after rejects Novo Nordisk's $3.1 billion biotech bid

COPENHAGEN/BRUSSELS Denmark's Novo Nordisk, the world's biggest insulin maker, went public with a 2.6 billion euro ($3.1 billion) bid for Belgian biotech group Ablynx on Monday, seeking a new source of growth by bolstering its treatments for rare blood disorders.

08 Jan 2018

Ablynx soars after rejects Novo Nordisk's $3.1 billion biotech bid

COPENHAGEN/BRUSSELS Denmark's Novo Nordisk, the world's biggest insulin maker, went public with a 2.6 billion euro ($3.1 billion) bid for Belgian biotech group Ablynx on Monday, seeking a new source of growth by bolstering its treatments for rare blood disorders.

08 Jan 2018

UPDATE 6-Ablynx soars after rejects Novo Nordisk's $3.1 bln biotech bid

* Bid underlines demand for biotech assets from large firms (Updates with exit of Ablynx chairman, closing share price)

08 Jan 2018

LIVE MARKETS-Closing snapshot: Europe holds up as big falls hit UK stocks

* New year rally gathers pace as autos cement rally * STOXX 600 hits highest since August 2015 * Novo offers to buy Ablynx at 32 pct premium * Dialog Semi jumps after Q4 sales beat guidance * But weak results weigh on British stocks Jan 8 Welcome to the home for real time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Danilo Masoni. Reach him on Messenger to share your thoughts on market moves: danilo.maso

08 Jan 2018

BRIEF-Ablynx's Board Says Takeover Proposal From Novo Nordisk Undervalues Company

* BOARD UNANIMOUSLY CONCLUDED THAT PROPOSAL FUNDAMENTALLY UNDERVALUES ABLYNX AND ITS STRONG PROSPECTS FOR CONTINUED GROWTH AND VALUE CREATION

08 Jan 2018

Novo Nordisk bids $3.1 billion for Belgian biotech group Ablynx

BRUSSELS Denmark's Novo Nordisk , the world's biggest maker of insulin, has made a 2.6 billion euro ($3.1 billion) bid for Belgian biotech group Ablynx as it seeks to diversify and strengthen its business for treating rare blood disorders.

08 Jan 2018

Weak results weigh on FTSE 100, profit warning pummels Mothercare

* Baby goods retailer Mothercare sinks 27 pct on poor Xmas trading

08 Jan 2018

Earnings vs. Estimates